- Global collaboration will provide more personalized diagnosis and therapy solutions for cancer patients
- Agreement to include research and exchange of technologies and solutions to provide access to proton therapy solutions and enhance oncology care centers across the globe
Louvain-la-Neuve, Belgium and Andover, MA, USA, 17-9-2014 — /EuropaWire/ — IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy and radiopharmacy solutions, and Royal Philips (NYSE: PHG AEX: PHIA), today announce the signing of a global collaboration to provide advanced diagnostic and therapeutic solutions for the treatment of cancer.
The collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. By merging their respective expertise in therapy and image guidance systems, IBA and Philips will innovate with an integrated vision for more efficient, personalized cancer care. Leveraging high quality imaging and proton therapy offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment, while reducing the cost of treatment for the healthcare system.
The collaboration will also enable both organizations to mutually leverage technologies and solutions: IBA will benefit from Philips diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. The commercial collaboration also includes an integrated offering for Molecular Imaging Centers, combining IBA’s expertise in PET radioisotope production centers with Philips imaging and diagnostics expertise.
Olivier Legrain, Chief Executive Officer of IBA commented: “This is an exciting and important step for IBA. A closer collaboration with a company of Philips’ caliber and global reach, where we are able to combine both companies’ expertise and excellence in oncology care, will accelerate innovation and provide more efficient and effective solutions in molecular imaging and treatment solutions. This collaboration is an important step toward adaptive treatment of cancer and a personalized treatment approach to enable the best possible result for cancer patients across the globe.”
Gene Saragnese, Executive Vice President and CEO, Imaging Systems, Philips added: “Proton therapy is one of the most exciting technological advancements in the oncology field. We look forward to collaborating with IBA to enhance access to best-in-class technology for both Proton Centers and Molecular Imaging Centers, as well as to accelerate the development of our informed therapy guidance vision in ways that can change the future of care, and improve the quality of life for patients.”
For further information please contact:
IBA Chief Financial Officer
Tel: +32 10 47 58 90
Vice-President Corporate Communication
+32 10 47 58 90
For media and investor enquiries:
Consilium Strategic Communications
Amber Bielecka, Mary-Jane Elliott, Matthew Neal, Jessica Hodgson and Ivar Milligan
+44 (0) 203 709 5700
Tel: +1 978-659-3748
Mobile: +1 978-760-9007
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 113,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.